PDGFRB and neoplasm: For example, Zhang et al. [18] have shown that a combination of Vorinostat (SAHA, 1) and the antiangiogenic kinase inhibitor Sorafenib, acting on RAF kinase and the VEGFR-2/PDGFR-β pathway, exhibited in vivo synergism on death induction in different tumor cytotypes.